101 2024 Vol.45 No.1
2024 年第 45 卷第 1 期 药事管理
若新增适应证带来的未来两年基金支出不超过原支
出的 100%,则按规则直接调整或降价,最多降低
15% ;其余则通过谈判降价,预计降价幅度远大于直
接降价。在此基础上,应结合药品联用的特点,明
确已准入药品新增联用适应证的管理。考虑到对已
准入药品重新开发的鼓励及患者增量的有限性,若
新增的联用适应证目标人群与该药品已有单药适应
证相同,则建议采取直接调整的方式,并适当缩小
降价的比例。由于已准入药品企业可能因降价缺乏
扩大支付范围的动力或引起不满,导致联用方案中
部分药品无法报销,影响患者对联用方案可及性,
因此还需进一步优化政策,激励已准入药品的开发
和准入积极性。发展按适应证差别定价的模式将是
未来值得探索的方向,这能从根本上提高已准入药
品开发新适应证的积极性。
参考文献:
[1] Ascierto PA, Marincola FM. Combination therapy: the next
opportunity and challenge of medicine[J]. J Transl Med, 2011,
9: 115.
[2] Triangle Insights Group. Combination therapy in oncology:
key trends, drivers, and future management among US
payers report by trigle insight group[EB/OL]. (2022-09-15)
[2023-04-06]. https://triangleinsightsgroup.com/wp-content/
uploads/2022/09/57-PMA-Oncology-White-Paper_.pdf.
[3] Briggs AH, Doyle A, Schneider J, et al. An attribution of value
framework for combination therapies[C]. 2021
[4] Latimer NR, Towse A, Henshall C. Not cost-effective at
zero price: valuing and paying for combination therapies in
cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2021,
21(3): 331-333.
[5] Towse A, Lothgren M, Steuten L, et al. Why we need a new
outcomes-based value attribution framework for combination
regimens in oncology[J]. Value Health, 2022, 14: S1098-
3015(22)02064-2.
[6] Izmirlieva MA, Reinaud F, Taiyeb M, et al. P29 reimbursement
outcomes for combination therapies vs monotherapies in
lung cancer and multiple myeloma in the top five european
markets[J]. Value Health, 2022, 25(1): S7.
[7] Pistollato M, Wilsdon T, Steele R, et al. PCN36 oncology
combinations: how to ensure timely access[J]. Value Health,
2021, 24(Supl 1): S25.
[8] Dd A, Jyb B, Lpg C. Challenges in the value assessment,
pricing and funding of targeted combination therapies in
oncology[J]. Health Policy, 2019, 123(12): 1230-1236.
[9] 王宏宇, 丁锦希, 李伟, 等. 联合用药医保准入评估模式研究
[J]. 中国医疗保险, 2022, (9): 6.
[10] Shibuya K, Hashimoto H, Ikegami N, et al. Future of Japan's
system of good health at low cost with equity: beyond
universal coverage[J]. Lancet, 2011, 378(9798): 1265-1273.
[11] Sakamoto H, Rahman MM, Nomura S, et al. Japan health
system review[M]. Tokyo: World Health Organization,
Regional Office for South-East Asia, 2018.
[12] Takayama A, Narukawa M. Pharmaceutical pricing and
reimbursement in Japan: for faster, more complete access to
new drugs[J]. Ther Innov Regul Sci, 2016, 50(3): 361-367.
[13] Ministry of Health, Labour and Welfare of Japan. Japan's NHI
drug price system[EB/OL]. (2022-03-08)[2023-04-06].
https://www.pmda.go.jp/files/000248690.pdf.
[14] Ministry of Health and Welfare. On the standard of calculation
of medical value[EB/OL]. (2022-02-09)[2023-04-06].
https://www.mhlw.go.jp/content/12404000/000896569.pdf.
[15] Latimer N, Pollard D. Pre-read document 1 : challenges in
valuing and paying for combination regimens in oncology[EB/
OL]. [2023-04-06]. https://www.researchgate.net/.
[16] Ministry of Health and Welfare. Update of drug pricing system
in Japan[EB/OL]. (2018-04-12)[2023-04-06]. https://www.
mhlw.go.jp/content/11123000/000335166.pdf.
[17] Ministry of Health and Welfare. New drug list (scheduled
for August 27,1995)[EB/OL]. (2013-08-27)[2023-04-
06]. https://www.mhlw.go.jp/file/05-Shingikai-12404000-
Hokenkyoku-Iryouka/0000016161.pdf.
[18] Examination and Control Division. Report of the deliberation
result[EB/OL]. (2013-05-21)[2023-04-06]. https://www.
pmda.go.jp/drugs/2013/P201300075/450045000_22500A
MX01001000_A100_1.pdf.
[19] Ministry of Health and Welfare. New drug list (scheduled to be
seated on September 2, 2010)[EB/OL]. (2014-09-02)[2023-
04-06]. https://www.mhlw.go.jp/file/05-Shingikai-12404000-
Hokenkyoku-Iryouka/0000055583.pdf.
[20] Ministry of Health and Welfare. List of new drugs (February
26, 2001)[EB/OL]. (2019-02-26)[2023-04-06]. https://
www.mhlw.go.jp/content/12404000/000501232.pdf.